Edison Investment Research

In a quickview note, Edison Investment Research expects Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to present growing revenues on broad pipeline opportunities. According to Edison, “End-September cash and equivalents was $13.6m; $15m+ is guided at end-FY11. FY11 guidance is for revenue of c $26m...

Edison Investment Research writes about Endocyte (NASDAQ: ECYT), “Concerns about delays in recruitment into Endocyte's Phase III study of the folatereceptor targeted anticancer EC145, stemming from a supply shortage of the coadministered Doxil (pegylated liposomal doxorubicin, PLD), have caused a...

Edison Investment Research writes about Curis (NASDAQ: CRIS), “The US FDA's acceptance for review of Roche's vismodegib NDA for the treatment of advanced inoperable basal cell carcinoma should substantially de-risk the investment case for its partner Curis. The agency's decision triggers an $8m...

Edison writes about OncoGenex Pharmaceuticals (NASDAQ: OGXI), “OncoGenex's lead product, custirsen, is being overshadowed by other castrateresistant prostate cancer (CRPC) drugs, including abiraterone and Alpharadin. However, it could have a similar impact. Impressive survival benefits have been...

Edison Investment Research has published a research report on Yukon-Nevada Gold (TSE: YNG). In the report, Edison Research Investment wrote, "Employing the services of an experienced Nevada geologist has resulted in total NI 43-101 compliant resources at Jerritt Canyon increasing to 3.43Moz (vs 2....

Edison Investment Research provided color on Micromet's (NASDAQ: MITI) collaboration with Amgen (NASDAQ: AMGN) in a research report published today. In the report, Edison Investment Research states, "Micromet has formed a major collaboration with Amgen to develop its BiTE antibodies to treat solid...

Edison Investment Research provided color on Synta Pharmaceuticals (NASDAQ: SNTA) in a research note published today. In the report, Edison states, "Synta is in intense negotiations with multiple potential partners on ganetespib and elesclomol in NSCLC and intends to conclude one or more licensing...